Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

被引：4

作者：

Ghose, Aruni ^{[1
,2
,3
,4
,5
,6
,7
,8
]}

Lapitan, Patricia ^{[7
,8
,9
,10
,11
]}

Apte, Vedika ^{[12
,13
]}

Ghosh, Adheesh ^{[10
]}

Kandala, Abhinav ^{[12
]}

Basu, Sreejana ^{[10
,13
]}

Parkes, Jo ^{[5
,14
,15
]}

Shinde, Sayali D. ^{[16
]}

Boussios, Stergios ^{[2
,17
,18
,19
,20
]}

Sharma, Anand ^{[3
,4
]}

Das, Prantik ^{[21
,22
]}

Vasdev, Nikhil ^{[4
,23
,24
]}

Rebuzzi, Sara E. ^{[6
,25
,26
]}

Urun, Yuksel ^{[27
,28
]}

Kanesvaran, Ravindran ^{[29
,30
]}

Maniam, Akash ^{[31
,32
,33
]}

Banna, Giuseppe L. ^{[6
,31
,32
]}

机构：

[1] Barts Hlth NHS Trust, St Bartholomews Hosp, Barts Canc Ctr, Dept Med Oncol, London, England

[2] Medway NHS Fdn Trust, Dept Med Oncol, Gillingham, Kent, England

[3] Mt Vernon Canc Ctr, Dept Med Oncol, Mt Vernon & Watford NHS Trust, Watford, England

[4] East & North Herts NHS Trust, Lister Hosp, Hertfordshire & Bedfordshire Urol Canc Ctr, Dept Urol, Stevenage, England

[5] Immunooncol Clin Network, London, England

[6] Italian Network Res Urooncol, Meet URO Grp, Milan, Italy

[7] British Oncol Network Undergrad Soc, London, England

[8] United Kingdom & Ireland Global Canc Network, London, England

[9] Univ Manchester, Sch Med Sci, Manchester, England

[10] UCL, UCL Canc Inst, London, England

[11] Inst Canc Res, Div Genet & Epidemiol, Surrey, England

[12] UCL, Med Sch, London, England

[13] UCL, Oncol Soc, London, England

[14] Worcestershire Acute Hosp NHS Trust, Worcestershire Oncol Ctr, Worcester, England

[15] British Oncol Pharm Assoc, London, England

[16] Univ Southampton, Univ Hosp Southampton NHS Fdn Trust, Canc Acad Sci Unit, Southampton, England

[17] Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, London, England

[18] Canterbury Christ Church Univ, Fac Med Hlth & Social Care, Canterbury, England

[19] Univ Kent, Kent & Medway Med Sch, Canterbury, England

[20] AELIA Org, 9th Km Thessaloniki Thermi, Thessaloniki 57001, Greece

[21] Univ Hosp Derby & Burton NHS Fdn Trust, Dept Oncol, Derby, England

[22] Univ Nottingham, Sch Med, Nottingham, England

[23] Univ Hertfordshire, Sch Life & Med Sci, Hatfield, England

[24] Apollo Hosp Educ & Res Fdn AHERF, Chennai, India

[25] Osped San Paolo, Med Oncol Unit, Savona, Italy

[26] Univ Genoa, Dept Internal Med & Med Specialties, Genoa, Italy

[27] Ankara Univ, Sch Med, Dept Med Oncol, Ankara, Turkiye

[28] Ankara Univ, Canc Res Inst, Ankara, Turkiye

[29] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore

[30] Duke NUS Med Sch, SingHlth Duke NUS Oncol Acad Clin Programme, Singapore, Singapore

[31] Portsmouth Hosp Univ NHS Trust, Dept Med Oncol, Portsmouth, England

[32] Univ Portsmouth, Fac Sci & Hlth, Sch Pharm & Biomed Sci, Portsmouth, England

[33] Caribbean Canc Res Inst, Port Of Spain, Trinidad Tobago

来源：

CURRENT ONCOLOGY REPORTS | 2024年 / 26卷 / 06期

关键词：

Antibody drug conjugate; Urology; Cancer; Chemotherapy; Urothelial; Renal; Testicular; Prostate; ACUTE MYELOID-LEUKEMIA; GEMTUZUMAB OZOGAMICIN; ENFORTUMAB VEDOTIN; THERAPY; CHEMOTHERAPY; MANAGEMENT; RESISTANCE; MYLOTARG; EFFICACY; PHASE-3;

D O I：

10.1007/s11912-024-01524-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of ReviewOur review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care.Recent FindingsADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape.SummaryADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.

引用

页码：633 / 646

页数：14

共 68 条

[1]

Aggarwal RR, 2022, J CLIN ONCOL, V40

[2] Management of stage II seminoma: a contemporary UK perspective [J].

Alifrangis, Constantine ;

Nicol, David L. ;

Shamash, Jonathan ;

Rajan, Prabhakar .

SCOTTISH MEDICAL JOURNAL, 2022, 67 (03) :126-128

[3] Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery [J].

Alifrangis, Constantine ;

Lucas, Olivia ;

Benafif, Sarah ;

Ansell, Wendy ;

Greenwood, Michelle ;

Smith, Shievon ;

Wilson, Peter ;

Thomas, Ben ;

Rudman, Sarah ;

Mazhar, Danish ;

Berney, Dan ;

Shamash, Jonathan .

EUROPEAN UROLOGY FOCUS, 2021, 7 (04) :835-842

[4] FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer [J].

Amiri-Kordestani, Laleh ;

Blumenthal, Gideon M. ;

Xu, Qiang Casey ;

Zhang, Lijun ;

Tang, Shenghui W. ;

Ha, Linan ;

Weinberg, Wendy C. ;

Chi, Bo ;

Candau-Chacon, Reyes ;

Hughes, Patricia ;

Russell, Anne M. ;

Miksinski, Sarah Pope ;

Chen, Xiao Hong ;

McGuinn, W. David ;

Palmby, Todd ;

Schrieber, Sarah J. ;

Liu, Qi ;

Wang, Jian ;

Song, Pengfei ;

Mehrotra, Nitin ;

Skarupa, Lisa ;

Clouse, Kathleen ;

Al-Hakim, Ali ;

Sridhara, Rajeshwari ;

Ibrahim, Amna ;

Justice, Robert ;

Pazdur, Richard ;

Cortazar, Patricia .

CLINICAL CANCER RESEARCH, 2014, 20 (17) :4436-4441

[5] Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors [J].

Ashkar, Ryan ;

Feldman, Darren R. ;

Adra, Nabil ;

Zaid, Mohammad Abu ;

Funt, Samuel A. ;

Althouse, Sandra K. ;

Perkins, Susan M. ;

Snow, Christin I. ;

Lazzara, Kayla M. ;

Sego, Lina M. ;

Quinn, David I. ;

Hanna, Nasser H. ;

Einhorn, Lawrence H. ;

Albany, Costantine .

INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) :1656-1663

[6] Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol [J].

Attard, Gerhardt ;

Murphy, Laura ;

Clarke, Noel W. ;

Sachdeva, Ashwin ;

Jones, Craig ;

Hoyle, Alex ;

Cross, William ;

Jones, Robert J. ;

Parker, Christopher C. ;

Gillessen, Silke ;

Cook, Adrian ;

Brawley, Chris ;

Gilson, Clare ;

Rush, Hannah ;

Abdel-Aty, Hoda ;

Amos, Claire L. ;

Murphy, Claire ;

Chowdhury, Simon ;

Malik, Zafar ;

Russell, J. Martin ;

Parkar, Nazia ;

Pugh, Cheryl ;

Diaz-Montana, Carlos ;

Pezaro, Carmel ;

Grant, Warren ;

Saxby, Helen ;

Pedley, Ian ;

O'Sullivan, Joe M. ;

Birtle, Alison ;

Gale, Joanna ;

Srihari, Narayanan ;

Thomas, Carys ;

Tanguay, Jacob ;

Wagstaff, John ;

Das, Prantik ;

Gray, Emma ;

Alzouebi, Mymoona ;

Parikh, Omi ;

Robinson, Angus ;

Montazeri, Amir H. ;

Wylie, James ;

Zarkar, Anjali ;

Cathomas, Richard ;

Brown, Michael D. ;

Jain, Yatin ;

Dearnaley, David P. ;

Mason, Malcolm D. ;

Gilbert, Duncan ;

Langley, Ruth E. ;

Millman, Robin .

LANCET ONCOLOGY, 2023, 24 (05) :443-456

[7] The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer [J].

Avellini, Chiara ;

Licini, Caterina ;

Lazzarini, Raffaella ;

Gesuita, Rosaria ;

Guerra, Emanuela ;

Tossetta, Giovanni ;

Castellucci, Clara ;

Giannubilo, Stefano Raffaele ;

Procopio, Antonio ;

Alberti, Saverio ;

Mazzucchelli, Roberta ;

Olivieri, Fabiola ;

Marzioni, Daniela .

ONCOTARGET, 2017, 8 (35) :58642-58653

[8] Renal Cell Cancer - Insights in Drug Resistance Mechanisms [J].

Aweys, Halima ;

Lewis, Deisha ;

Sheriff, Matin ;

Rabbani, Rukhshana Dina ;

Lapitan, Patricia ;

Sanchez, Elisabet ;

Papadopoulos, Vasileios ;

Ghose, Aruni ;

Boussios, Stergios .

ANTICANCER RESEARCH, 2023, 43 (11) :4781-4792

[9] Exosomes in the Diagnosis and Treatment of Renal Cell Cancer [J].

Boussios, Stergios ;

Devo, Perry ;

Goodall, Iain C. A. ;

Sirlantzis, Konstantinos ;

Ghose, Aruni ;

Shinde, Sayali D. ;

Papadopoulos, Vasileios ;

Sanchez, Elisabet ;

Rassy, Elie ;

Ovsepian, Saak V. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)

[10] Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial [J].

Brown, Janet E. ;

Royle, Kara-Louise ;

Gregory, Walter ;

Ralph, Christy ;

Maraveyas, Anthony ;

Din, Omar ;

Eisen, Timothy ;

Nathan, Paul ;

Powles, Tom ;

Griffiths, Richard ;

Jones, Robert ;

Vasudev, Naveen ;

Wheater, Matthew ;

Hamid, Abdel ;

Waddell, Tom ;

McMenemin, Rhona ;

Patel, Poulam ;

Larkin, James ;

Faust, Guy ;

Martin, Adam ;

Swain, Jayne ;

Bestall, Janine ;

McCabe, Christopher ;

Meads, David ;

Goh, Vicky ;

Wah, Tze Min ;

Brown, Julia ;

Hewison, Jenny ;

Selby, Peter ;

Collinson, Fiona .

LANCET ONCOLOGY, 2023, 24 (03) :213-227

← 1 2 3 4 5 6 7 →